Literature DB >> 29796761

Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient.

Ester M van Leeuwen1, Eloy Cuadrado2, Anke M Gerrits3, Esther Witteveen4, Godelieve J de Bree5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29796761     DOI： 10.1007/s10875-018-0511-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


× No keyword cloud information.
  5 in total

1.  Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4.

Authors:  Sangmoon Lee; Jin Soo Moon; Cho-Rong Lee; Hye-Eun Kim; Sun-Mi Baek; Solha Hwang; Gyeong Hoon Kang; Jeong Kee Seo; Choong Ho Shin; Hyoung Jin Kang; Jae Sung Ko; Sung Gyoo Park; Murim Choi
Journal:  J Allergy Clin Immunol       Date:  2015-10-21       Impact factor: 10.793

2.  Assessment of CTLA-4 Deficiency-Related Autoimmune Choroidopathy Response to Abatacept.

Authors:  Carol L Shields; Emil A T Say; Arman Mashayekhi; Sunir J Garg; James P Dunn; Jerry A Shields
Journal:  JAMA Ophthalmol       Date:  2016-07-01       Impact factor: 7.389

3.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.

Authors:  Hye Sun Kuehn; Weiming Ouyang; Bernice Lo; Elissa K Deenick; Julie E Niemela; Danielle T Avery; Jean-Nicolas Schickel; Dat Q Tran; Jennifer Stoddard; Yu Zhang; David M Frucht; Bogdan Dumitriu; Phillip Scheinberg; Les R Folio; Cathleen A Frein; Susan Price; Christopher Koh; Theo Heller; Christine M Seroogy; Anna Huttenlocher; V Koneti Rao; Helen C Su; David Kleiner; Luigi D Notarangelo; Yajesh Rampertaap; Kenneth N Olivier; Joshua McElwee; Jason Hughes; Stefania Pittaluga; Joao B Oliveira; Eric Meffre; Thomas A Fleisher; Steven M Holland; Michael J Lenardo; Stuart G Tangye; Gulbu Uzel
Journal:  Science       Date:  2014-09-11       Impact factor: 47.728

4.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

5.  Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.

Authors:  Desirée Schubert; Claudia Bode; Rupert Kenefeck; Tie Zheng Hou; Lucy S K Walker; David M Sansom; Bodo Grimbacher; James B Wing; Alan Kennedy; Alla Bulashevska; Britt-Sabina Petersen; Alejandro A Schäffer; Björn A Grüning; Susanne Unger; Natalie Frede; Ulrich Baumann; Torsten Witte; Reinhold E Schmidt; Gregor Dueckers; Tim Niehues; Suranjith Seneviratne; Maria Kanariou; Carsten Speckmann; Stephan Ehl; Anne Rensing-Ehl; Klaus Warnatz; Mirzokhid Rakhmanov; Robert Thimme; Peter Hasselblatt; Florian Emmerich; Toni Cathomen; Rolf Backofen; Paul Fisch; Maximilian Seidl; Annette May; Annette Schmitt-Graeff; Shinji Ikemizu; Ulrich Salzer; Andre Franke; Shimon Sakaguchi
Journal:  Nat Med       Date:  2014-10-20       Impact factor: 53.440
  5 in total
  10 in total

1.  Regulatory T cell features in chronic granulomatous disease.

Authors:  A van de Geer; E Cuadrado; M C Slot; R van Bruggen; D Amsen; T W Kuijpers
Journal:  Clin Exp Immunol       Date:  2019-04-16       Impact factor: 4.330

2.  Neurological Involvement in Childhood Evans Syndrome.

Authors:  Thomas Pincez; Bénédicte Neven; Hubert Ducou Le Pointe; Pascale Varlet; Helder Fernandes; Albane Gareton; Guy Leverger; Thierry Leblanc; Hervé Chambost; Gérard Michel; Marlène Pasquet; Frédéric Millot; Olivier Hermine; Alexis Mathian; Marie Hully; Hélène Zephir; Mohamed Hamidou; Jean-Marc Durand; Yves Perel; Judith Landman-Parker; Fréderic Rieux-Laucat; Nathalie Aladjidi
Journal:  J Clin Immunol       Date:  2019-01-22       Impact factor: 8.317

3.  A Rare Central Nervous System Involvement Due to CTLA-4 Gene Defect.

Authors:  Sahib Rovshanov; Rahşan Göçmen; İbrahim Barişta; Deniz Çağdaş; Ayşegül Üner; Vedat Çilingir; İrsel Tezer Filik; Çağman Tan; Elif Soyak Aytekin; İlhan Tezcan; Pınar Acar Özen; Aslı Tuncer
Journal:  Noro Psikiyatr Ars       Date:  2022-08-15       Impact factor: 1.066

4.  Tailored therapies for primary immunodeficiencies.

Authors:  Bianca Cinicola; Federica Pulvirenti; Giulia Brindisi; Gian Luigi Marseglia; Riccardo Castagnoli; Thomas Foiadelli; Carlo Caffarelli; Amelia Licari; Michele Miraglia Del Giudice; Anna Maria Zicari; Marzia Duse; Fabio Cardinale
Journal:  Acta Biomed       Date:  2021-11-29

Review 5.  Beyond monogenetic rare variants: tackling the low rate of genetic diagnoses in predominantly antibody deficiency.

Authors:  Emily S J Edwards; Julian J Bosco; Samar Ojaimi; Robyn E O'Hehir; Menno C van Zelm
Journal:  Cell Mol Immunol       Date:  2020-08-17       Impact factor: 11.530

6.  The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay.

Authors:  C Kelaidi; V Tzotzola; S Polychronopoulou
Journal:  Fam Cancer       Date:  2021-06-15       Impact factor: 2.375

Review 7.  The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders.

Authors:  Danielle E Arnold; Deepak Chellapandian; Jennifer W Leiding
Journal:  Front Immunol       Date:  2021-06-24       Impact factor: 7.561

8.  Myeleterosis in an ALPS5 patient with primary immune dysregulation syndrome.

Authors:  Hongyu Long; Zhao Chen; Bo Xiao; Beisha Tang; Hong Jiang
Journal:  CNS Neurosci Ther       Date:  2020-03-17       Impact factor: 5.243

Review 9.  Recent advances in primary immunodeficiency: from molecular diagnosis to treatment.

Authors:  Giorgia Bucciol; Isabelle Meyts
Journal:  F1000Res       Date:  2020-03-19

10.  A Family with a Novel CTLA4 Haploinsufficiency Mutation and Neurological Symptoms.

Authors:  Alexandros Grammatikos; Sarah Johnston; Claire M Rice; Mark Gompels
Journal:  J Clin Immunol       Date:  2021-05-06       Impact factor: 8.317
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.